E 7766
Alternative Names: E-7766Latest Information Update: 04 Aug 2023
At a glance
- Originator Eisai Inc
- Class Antineoplastics; Macrocyclic compounds
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Bladder cancer; Lymphoma
Most Recent Events
- 04 Aug 2023 E 7766 is still in phase I trials for Solid tumours in France, Spain, USA (Eisai pipeline, August 2023)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in France (Intratumoural, Injection)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Injection)